menu search

DBTX / Decibel Therapeutics to Participate in Upcoming Investor Conferences

Decibel Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March. Read More
Posted: Mar 22 2022, 07:30
Author Name: GlobeNewsWire
Views: 111024

DBTX News  

Decibel Therapeutics' CVR Appears Around Fair Value

By Seeking Alpha
September 15, 2023

Decibel Therapeutics' CVR Appears Around Fair Value

Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hear more_horizontal

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals

By Investopedia
August 9, 2023

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals

Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene th more_horizontal

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal

By InvestorPlace
August 9, 2023

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal

Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This de more_horizontal

Decibel Therapeutics shoots up 72% on Regeneron bid

By Proactive Investors
August 9, 2023

Decibel Therapeutics shoots up 72% on Regeneron bid

Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be more_horizontal

Regeneron buying small cap Decibel Therapeutics for $4 a share

By Market Watch
August 9, 2023

Regeneron buying small cap Decibel Therapeutics for $4 a share

Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its more_horizontal

Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study

By Benzinga
June 28, 2022

Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study

Decibel Therapeutics Inc (NASDAQ: DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-02 more_horizontal

Decibel Therapeutics to Participate in Upcoming Investor Conferences

By GlobeNewsWire
March 22, 2022

Decibel Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and de more_horizontal


Search within

Pages Search Results: